2025 was a pivotal year in cardiovascular medicine, marked by significant advancements and paradigm shifts in treatment and risk assessment. The field witnessed groundbreaking research and updated guidelines that reshaped clinical practice, particularly in interventional cardiology. One of the most notable developments was the reevaluation of aspirin's role in cardiovascular health.
Research released in 2025 challenged long-held assumptions about aspirin's benefits. The Medical Republic reported on several large studies, including findings that routine aspirin use does not provide significant benefits and may even increase risks. These studies concluded that lifelong aspirin use was based on outdated evidence, and superior antiplatelet therapies like clopidogrel could replace aspirin as the preferred choice. In fact, one clinical trial had to be halted early due to excess deaths, prompting clinicians to reconsider their prescribing practices.
The studies revealed that aspirin, when used alongside anticoagulation therapy, failed to reduce the risk of stent thrombosis, the primary reason for long-term aspirin use after stent implantation. Instead, it increased all-cause mortality by a staggering 72%. This led to a significant shift in clinical practice, with a focus on alternative therapies.
Another major development in 2025 was the push for single-pill combinations (SPCs) or fixed-dose combinations (FDCs) as first-line hypertension treatment. This prompted urgent calls for changes to the Pharmaceutical Benefits Scheme (PBS) in Australia. However, despite the publication of the article in August, the PBS restrictions have not been lifted, and updates to the Australian Hypertension Guidelines, expected at the end of 2025, have not been released.
Australian researchers also made a groundbreaking discovery in CRISPR gene-editing technology. They conducted the first in-human trial that successfully used gene-editing to manage cholesterol. A single injection of editing tools led to significant reductions in both cholesterol and triglycerides, marking a potential breakthrough in treating mixed lipid disorders.
In the realm of lipids, the European Society of Cardiology and the European Atherosclerosis Society released new international recommendations for dyslipidaemia management. These guidelines proposed a more aggressive approach to lipid-lowering regimens, moving away from the traditional 'low and slow' tactic. They also emphasized the importance of utilizing Lp(a) testing for heart disease prevention, a long-overlooked risk factor. According to research released in 2025, routine Lp(a) screening could prevent a significant number of heart attacks, strokes, and early deaths.
The annual American Heart Association scientific sessions showcased numerous studies, with a notable focus on PCSK9 inhibitors in cholesterol management. One study found that pairing PCSK9 inhibitors with statins provided additional protection, reducing the risk of cardiovascular death, heart attack, or ischemic stroke by more than 25%.
Cardiologists from Italy, Germany, and the US, in a viewpoint published in the European Heart Journal, highlighted the transformative impact of pivotal randomized clinical trials on interventional cardiology in 2025. These trials refined antiplatelet management after percutaneous coronary intervention (PCI), clarified the optimal timing of multivessel revascularization in ST-elevation myocardial infarction, and enhanced our understanding of transcatheter aortic valve implantation (TAVI) durability in low-risk patients. These advancements have reshaped daily practice and sharpened procedural strategies, setting new long-term expectations for percutaneous therapies.
